Browsing by Author "Aras, A"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item QUALITY-OF-LIFE ASSESSMENT OF APPLIED THERAPY TO BREAST CANCER PATIENTSSert, F; Özsaran, Z; Eser, E; Alanyali, S; Haydaroglu, A; Aras, AObjective: Quality-of-Life (QoL) has an important role for breast cancer patients when considering long life expectancy. The main purpose of this study is evaluating the impact of hormonal therapy upon QoL, which is applied after radiotherapy, in the light of realistic data. Materials and Methods: The breast cancer patients treated with adjuvant radiotherapy at Ege University Hospital between January 2007 and December 2009 were evaluated for this trial after obtaining their informed consent FACT-Gv4 and FACT-ESv4 FACT-ES questionnaires were used for QoL evaluations. Obtained surveys were evaluated with the original guide of FACT. Results: A body mass index of over 30 was used as the obesity limit. There was a statistical significance between social well-being score and obesity (p=0.028). Functional well-being scores were statistically better for the patients without co-morbid disease (p=0.018). Endocrine subscale scores were deteriorated during hormonal therapy but they presented some increase in second evaluation but they did not reach basal levels (p=0.000 for all parameters). Conclusion: The diagnosis of breast cancer is affecting QoL independently of the applied treatment. When considering this, post-diagnosis and/or pretreatment physiological support is very important. Methods of treatment and the patient's demographic data are important factors that may affect the QoL. Assessment of QoL has an important role in terms of patient compliance to disease and treatment. For breast cancer patients who have a long life expectancy, multi-institutional QoL researches are needed for presenting the patient's beliefs and adherences to their therapy. We can provide more detailed and clear information with the help of future researches.Item BREAST CONSERVING SURGERY AND ADJUVANT RADIOTHERAPY FOR DUCTAL CARCINOMA INSITU: EXPERIENCE OF EGE UNIVERSITYBölükbasi, Y; Demirci, S; Özsaran, Z; Iscan, G; Çelik, OK; Haydaroglu, A; Aras, APurpose: To evaluate the treatment results of patients diagnosed with ductal carcinoma in situ (DCIS) treated with breast conserving surgery and adjuvant radiotherapy. Materials and Methods: Between 1991 and 2006, 46 patients were treated in Ege University Faculty of Medicine for DCIS, were analyzed retrospectively. All the patients underwent breast conserving surgery and adjuvant radiotherapy. Fifty Gy was delivered to whole breast through tangential portals. Boost dose was 10 Gy and it was given by photons in 3 (% 10.7) patients and electrons in 25 (% 89.3) patients. Results: Median age was 48 (range: 16- 66). Of the patients, 45.6% (21) were diagnosed by screening mammography, the others were presented with palpable mass (50%), pain (2.2%) and discharge (2.2%). The most common tumor localization was upper outer quadrant (63%). Comedo histopathology was detected in 7 patients (15.2%). After the surgery, cosmetic evaluation was as follows: 36.8% (14) excellent, 44.8% (17) good, 10.5% (4) satisfactory and 7.9% (3) fair. After radiotherapy cosmetic evaluation was performed at least 6 months after the end of treatment. The scores were found to be excellent in 34.2% (13) patients, good in 47.4% (18), satisfactory in 10.5% (4) and fair in 7.9% (3) patients (p= 0.564). Five and ten years disease free survival and local relaps free survival were 95.3%, 92.7% and 88.2%, 90.1%, respectively. Five and ten years overall survival 100% and for distant metastases free survival, these parameters were 100% and 88.3%, respectively. Conclusion: Partial mastectomy and adjuvant radiotherapy in the treatment of DCIS provides low recurrence rates and optimal cosmesis.Item Adverse effects of endocrine therapy in breast cancer: single institute experienceSert, F; Ozsaran, Z; Esen, E; Alanyali, S; Sert, I; Haydaoglu, A; Aras, AAim of the study: The main purpose of this study is to assess the known adverse effects of adjuvant endocrine therapy for non-metastatic breast cancer patients and to present our single center experience with light of literature. Material and methods: The breast cancer patients treated with adjuvant radiotherapy in Medical School of Ege University between January 2007 and December 2009 were evaluated for this trial after obtaining their acceptance. Vital findings, bone mineral densitometry, endometrium thickness measured with trans-vaginal ultrasonography, biochemical results including liver function tests and blood lipid profile (total cholesterol, HDL, LDL, VLDL, triglyceride) were recorded for each controls. Socio-demographic data, financial statuses, medical history, co-morbid diseases were obtained from first controls. Patients were followed without any local recurrence and distant metastases until June 2011. Results: Endometrium thickness was not seen in AI using patients. As compared with tamoxifen group, lack of thickness in AI group was statistically significant (p = 0.000). When compared the values before AI, the number of patients who had osteoporosis was gradually increasing. The decrease was seen in the number of patients with osteopenia. The number of patients with normal lipid profile was gradually increasing up to the second evaluation for tamoxifen group (p = = 0.000). On the other hand, the number of patients with hyperlipidemia was increasing for AIs group in follow-up period statistically (p = 0.006). Conclusions: With the aid of careful patient follow and effective disease management strategies, the negative effect over the QoL can be minimized and also the greatest benefit from endocrine therapy can be obtained.Item Quality of Life Assessment in Women with Breast Cancer: A Prospective Study Including Hormonal TherapySert, F; Ozsaran, Z; Eser, E; Alanyali, SD; Haydaroglu, A; Aras, APurpose: Evaluating the effect of hormonal treatment on quality of life (QoL) in breast cancer patients by using the Functional Assessment of Cancer Treatment (FACT) questionnaire is the main purpose of this trial. Methods: Breast cancer patients treated with adjuvant between January 2007 and December 2009 were evaluated. The first survey was done after patients completed their whole adjuvant treatment except for the hormonal therapy and this was as 'basal assessment.' The second survey was done 6 to 12 months after the basal surveys during their routine policlinic controls. The last survey was done within the last 18 to 24 months of the follow-up period. Results: The effect of marital status, number of pregnancies, residence in the village or city, hemoglobin levels, chemotherapy and hormonal therapy for any other reason except for breast cancer on the QoL could not be seen. Endocrine subscale scores were detected to be higher in patients aged >60 years than in younger ones. The other dimension scores were low in the elderly patient group. There was a statistically significant relationship between being >30 years old and improvement in the social well-being score (p=0.028). The functional well-being scores were found to be significantly higher in the patient group that had no comorbid disease (p=0.018). Endocrine subscale scores were statistically worse in patients who had psychiatric disease (p=0.057) but the general QoL data were similar with others. It was shown that all QoL scores for all dimensions had statistically significant changes (p<0.001) in terms of hormonal regimes. Conclusion: The diagnosis of breast cancer was found to be an independent factor that affects social well-being and social life in a negative way. We must give attention to complaints including complaints about sexual life and hormonal status in order to ensure compliance of patients with the required hormonal regimens. By the help of future research, we can improve the prognosis of this disease through increased treatment adherence and belief of patients.